title: Evaluation of in vivo antioxidant and immunity enhancing activities of sodium aescinate injection liquid.
abstract: Oxidative stress is involved in the development and progression of disease. Because sodium aescinate has been reported to have immunity enhancing and antioxidative effects, we investigated its activity by employing a hepatocellular carcinoma (HCC) mouse model. Sixty BALB/c mice were randomly divided into four groups, including a 1.4 mg/kg treated group (n = 15), a 2.8 mg/kg treated group (n = 15), an untreated hepatocellular carcinoma control group (n = 15) and a normal control group (n = 15). After H22 cells were cultured for one week, we collected 2 × 10⁶ cells and injected them subcutaneously as 0.2 mL cell suspensions in sterile saline into the right shoulder region of every mouse. The animals were monitored for changes in activity, physical condition and body weight during the experiment. The next day after injection of H22 cells, animals in these test groups received one intraperitoneal injection of drug or physiological saline for 13 days. Results showed that in the sodium aescinate injection liquid (SAIL)-treated HCC mice, serum interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), Gamma-glutamyltransferase (γ-GT), alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) levels were significantly decreased compared with normal control mice. In addition, treatment with sodium aescinate injection liquid significantly decreased blood and liver malondialdehyde (MDA) levels, increased glutathione (GSH) levels, and antioxidant enzyme [superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px)] activities in a dose-dependent manner. We conclude that sodium aescinate injection liquid can decrease oxidative injury and enhance immunity functions in HCC mice.
authors.affiliation: Department of Hepatobiliary & Pancreatic Diseases, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai 200120, China.
authors.forename: Yong-Kun
authors.initials: YK
authors.lastname: Wang
authors.forename: Jiang
authors.initials: J
authors.lastname: Han
authors.forename: Wu-Jun
authors.initials: WJ
authors.lastname: Xiong
authors.forename: Qiong-Ying
authors.initials: QY
authors.lastname: Yuan
authors.forename: Yan-Ping
authors.initials: YP
authors.lastname: Gu
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Zhe
authors.initials: Z
authors.lastname: Zhu
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Cong-Jun
authors.initials: CJ
authors.lastname: Wang
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001219:Aspartate Aminotransferases / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D007371:Interferon-gamma / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000032:analysis; D008113:Liver Neoplasms / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D018384:Oxidative Stress / Q000187:drug effects*; D011897:Random Allocation; D017670:Sodium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D023041:Xenograft Model Antitumor Assays; D005723:gamma-Glutamyltransferase / Q000378:metabolism
chemical_list: D000975:Antioxidants; D007155:Immunologic Factors; D053583:Interleukin-1beta; D015850:Interleukin-6; D017670:Sodium Compounds; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D013482:Superoxide Dismutase; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase